The immunosuppressive role of adenosine A2A receptors in Ischemia reperfusion injury and Islet transplantation

Current Diabetes Reviews

Volumn 8, Issue 6, 2012, Pages 419-433

  Chhabra, Preeti ^a   Linden, Joel ^b   Lobo, Peter ^a   Okusa, Mark Douglas ^a   Brayman, Kenneth Lewis ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Adenosine A2A receptors; Cytokines; Immune suppression; Inflammation; Ischemia reperfusion injury; Islet graft survival; Islet transplantation; Regulatory T cells; Type 1 diabetes

Indexed keywords

ADENOSINE A2A RECEPTOR;

ARTICLE; AUTOIMMUNITY; BRAIN ISCHEMIA; CD4+ CD25+ T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART MUSCLE ISCHEMIA; IMMUNOMODULATION; ISCHEMIA; KIDNEY ISCHEMIA; LIVER ISCHEMIA; LUNG; MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

ANIMALS; DENDRITIC CELLS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; KIDNEY; LIVER; LUNG; MACROPHAGES; MICE; MICE, KNOCKOUT; MYOCARDIUM; NEUTROPHILS; RECEPTOR, ADENOSINE A2A; REPERFUSION INJURY; T-LYMPHOCYTES, REGULATORY;

EID: 84870180598     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339912803529878     Document Type: Article

References (176)

1. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004; 25: 33-9.
2. Thiel M, Caldwell CC, Sitkovsky MV. The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect 2003; 5: 515-26.
3. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors- an update. Pharmacol Rev 2011; 63: 1-34.
4. Streitová D, Sefc L, Savvulidi F, Pospíšil M, Holá J, Hofer M. Adenosine A1, A2A, A2b, and A3 receptors in hematopoiesis. 1. Expression of receptor mRNA in four mouse hematopoietic precursor cells. Physiol Res 2010; 59: 133-7.
5. Linden J. Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 2005; 67: 1385-7.
6. Fredholm BB, Zhang Y, van der Ploeg I. Adenosine A2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phestimulated respiratory burst in neutrophil leucocytes. Naunyn- Schmiedeberg's Arch Pharmacol 1996; 354: 262-67.
7. Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol 2005; 174: 1073-80.
8. Desai A, Victor-Vega C, Gadangi S, Montesinos MC, Chu CC, and Cronsteiny BN. Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. Mol Pharmacol 2005; 67: 1406-13.
9. Sandberg G. Regulation of thymocyte proliferation by endogenous adenosine and adenosine deaminase. Int J Immunopharmacol 1983; 5: 259-65.
10. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-92.
11. Mirabet M, Herrera C, Cordero O J, Mallol J, Lluis C, Franco R. Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. J Cell Sci 1999; 112: 491-502.
12. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414: 916-20.
13. Linden J. Molecular approach to adenosine receptors: receptormediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001; 41: 775-87.
14. Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008; 7: 759-70.
15. Sullivan GW. Adenosine A2A receptor agonists as antiinflammatory agents. Curr Opin Investig Drugs 2003; 4: 1313-19.
16. Palmer TM, Trevethick MA. Suppression of inflammatory and immune responses by the A(2A) adenosine receptor: an introduction. Br J Pharmacol 2008; 153: S27-34.
17. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxiainducible factors and adenosine A2A receptors. Annu Rev Immunol 2004; 22: 657-82.
18. Szabo C, Scott GS, Virag L, et al. Suppression of macrophage inflammatory protein (MIP)-1alpha production and collageninduced arthritis by adenosine receptor agonists. Br J Pharmacol 1998; 125: 379-87.
19. Day YJ, Li Y, Rieger JM, Ramos SI, Okusa MD, Linden J. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J Immunol 2005; 174: 5040-6.
20. Németh ZH, Bleich D, Csóka B, et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 2007; 21: 2379-88.
21. Tsutsui S, Schnermann J, Noorbakhsh F, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 2004; 24: 1521-9.
22. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 2006; 203: 2639-48.
23. Day YJ, Marshall MA, Huang L, McDuffie MJ, Okusa MD, Linden J. Protection from Ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am J Physiol Gastrointest Liver Physiol 2004; 286: G285-93.
24. Li L, Huang L, Vergis AL, et al. IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J Clin Invest 2010; 120: 331-42.
25. Birdsall HH, Green DM, Trial J, et al. Complement C5a, TGF-b1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. Circulation 1997; 95: 684-92.
26. Odashima M, Otaka M, Jin M, et al. A selective A2A receptor agonist, ATL-146e, prevents concanavalin A-induced acute liver injury in mice. Biochem Biophys Res Commun 2006; 347: 949-54.
27. Day YJ, Huang L, Ye H, Li L, Linden J, Okusa MD. Renal ischemia- reperfusion injury and adenosine A2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol 2006; 176: 3108-14.
28. Okusa MD, Linden J, Macdonald T, Huang L. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol Renal Physiol 1999; 277: F404-12.
29. Ross SD, Tribble CG, Linden J, et al. Selective adenosine-A2A activation reduces lung reperfusion injury following transplantation. J Heart Lung Transplant 1999; 18: 994-1002.
30. Yang Z, Day YJ, Toufektsian MC, et al. Myocardial infarctsparing effect of A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 2006; 114: 2056-64.
31. Peirce SM, Skalak TC, Rieger JM, Macdonald TL, Linden J. Selective A(2A) adenosine receptor activation reduces skin pressure ulcer formation and inflammation. Am J Physiol Heart Circ Physiol 2001; 281: H67-74.
32. Cassada DC, Tribble CG, Long SM, et al. Adenosine A2A analogue ATL-146e reduces systemic tumor necrosing factor- and spinal cord capillary platelet-endothelial cell adhesion molecule-1 expression after spinal cord ischemia. J Vasc Surg 2002; 35: 994-8.
33. Lappas CM, Sullivan GW, Linden J. Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs 2005; 14: 797-806.
34. Sullivan GW, Rieger JM, Scheld WM, Macdonald TL, Linden J. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br J Pharmacol 2001; 132: 1017-26.
35. Raskovalova T, Lokshin A, Huang X, Jackson EK, Gorelik E. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I). Immunol Res 2006; 36: 91-9.
36. Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G. Concanavalin A induced T cell mediated hepatic injury in mice: the role of tumour necrosis factor. Hepatology 1995; 21: 190-8.
37. Choukèr A, Thiel M, Lukashev D, et al. Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway. Mol Med 2008; 14: 116-23.
38. Cao Z, Yuan Y, Jeyabalan G, et al. Preactivation of NKT cells with a-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor. Am J Physiol Gastrointest Liver Physiol 2009; 297: G249-58.
39. Hasko G, Kuhel DG, Chen JF, et al. Adenosine inhibits IL-12 and TNF-α production via adenosine A2A receptor-dependent and independent mechanisms. FASEB J 2000; 14: 2065-74.
40. Tang LM, Zhu JF, Wang F, et al. Activation of adenosine A2A receptor attenuates inflammatory response in a rat model of smallfor- size liver transplantation. Transplant Proc 2010; 42: 1915-20.
41. 2AR adenosine receptor controls cytokine production in iNKT cells. Eur J Immunol 2010; 40: 682-7.
42. Li L, Okusa MD. Blocking the immune response in ischemic acute kidney injury: the role of adenosine 2A agonists. Nat Clin Pract Nephrol 2006; 2: 432-44.
43. Day YJ, Huang L, McDuffie MJ, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrowderived cells. J Clin Invest 2003; 112: 883-91.
44. Lange-Sperandio B, Forbes MS, Thornhill B, Okusa MD, Linden J, Chevalier RL. A2A adenosine receptor agonist and PDE4 inhibition delays inflammation but fails to reduce injury in experimental obstructive nephropathy. Nephron Exp Nephrol 2005; 100: e113-23.
45. Awad AS, Huang L, Ye H, et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F828-37.
46. Garcia GE, Truong LD, Chen JF, Johnson RJ, Feng L. Adenosine A(2A) receptor activation prevents progressive kidney fibrosis in a model of immune-associated chronic inflammation. Kidney Int 2011; 80: 378-88.
47. Zhang L, Yang N, Wang S, et al. Adenosine 2A receptor is protective against renal injury in MRL/lpr mice. Lupus 2011; 20: 667-77.
48. Bolisetty S, Agarwal A. Neutrophils in acute kidney injury: not neutral any more. Kidney Int 2009; 75: 674-6.
49. Awad AS, Rouse M, Huang L, et al. Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. Kidney Int 2009; 75: 689-98.
50. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004; 66: 486-91.
51. Glover DK, Riou LM, Ruiz M, et al. Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective A2A receptor agonist, in reperfused canine myocardium. Am J Physiol Heart Circ Physiol 2005; 288: H1851-8.
52. Maddock HL, Broadley KJ, Bril A, Khandoudi N. Role of endothelium in ischaemia-induced myocardial dysfunction of isolated working hearts: cardioprotection by activation of adenosine A(2A) receptors. J Auton Pharmacol 2001; 21: 263-71.
53. Yang Z, Day YJ, Toufektsian MC, et al. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 2005; 111: 2190-7.
54. Rork TH, Wallace KL, Kennedy DP, Marshall MA, Lankford AR, Linden J. Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol 2008; 295: H1825-33.
55. Ponnoth DS, Sanjani MS, Ledent C, Roush K, Krahn T, Mustafa SJ. Absence of adenosine-mediated aortic relaxation in A2A adenosine receptor knockout mice. Am J Physiol Heart Circ Physiol 2009; 297: H1655-60.
56. Al Jaroudi W, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol 2009; 54: 1123-30.
57. Botvinick EH. Current methods of pharmacologic stress testing and the potential advantages of new agents. J Nucl Med Technol 2009; 37: 14-25.
58. Xi J, McIntosh R, Shen X, et al. Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol 2009; 47: 684-90.
59. Fozard JR, Ellis KM, Villela Dantas MF, Tigani B, Mazzoni L. Effects of CGS21680, a selective A2A receptor agonist, on allergic airways inflammation in the rat. Br J Pharmacol 2002; 438: 183-8.
60. Bonneau O, Wyss D, Ferretti S, Blaydon C, Stevenson CS, Trifilieff A. Effect of A2A receptor activation in murine models of respiratory disorders. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1036-43.
61. Thiel M, Chouker A, Ohta A, et al. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol 2005; 6: e174. Available from: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.0030174
62. Sharma AK, Linden J, Kron IL, Laubach VE. Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation. Respir Res 2009; 10: 58.
63. Sharma AK, Laubach VE, Ramos SI, et al. Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg 2010; 139: 474-82.
64. Lau CL, Zhao Y, Kron IL, et al. The role of adenosine A2A receptor signaling in bronchiolitis obliterans. Ann Thorac Surg 2009; 88: 1071-8.
65. Nadeem A, Fan M, Ansari HR, Ledent C, Mustafa SJ. Enhanced airway reactivity and inflammation in A2A adenosine receptor deficient allergic mice. Am J Physiol Lung Cell Mol Physiol 2007; 2: L1335-44.
66. Trevethick MA, Mantell SJ, Stuart EF, Barnard A, Wright KN, Yeadon M. Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions. Br J Pharmacol 2008; 155: 463-74.
67. LaPar DJ, Laubach VE, Emaminia A, et al. Pretreatment strategy with adenosine A2A receptor agonist attenuates reperfusion injury in a preclinical porcine lung transplantation model. J Thorac Cardiovasc Surg 2011; 142: 887-94.
68. Impellizzeri D, Di Paola R, Esposito E, et al. CGS 21680, an agonist of the adenosine (A2A) receptor, decreases acute lung inflammation. Eur J Pharmacol 2011; 668: 305-16.
69. Wallace KL, Linden J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 2010; 116: 5010-20.
70. Li Y, Oskouian RJ, Day YJ, et al. Mouse spinal cord compression injury is reduced by either activation of the adenosine A2A receptor on bone marrow-derived cells or deletion of the A2A receptor on non-bone marrow-derived cells. Neuroscience 2006; 141: 2029-39.
71. Reece TB, Tribble CG, Okonkwo DO, et al. Early adenosine receptor activation ameliorates spinal cord reperfusion injury. J Cardiovasc Med 2008; 9: 363-7.
72. Genovese T, Melani A, Esposito E, et al. Selective adenosine A(2a) receptor agonists reduce the apoptosis in an experimental model of spinal cord trauma. J Biol Regul Homeost Agents 2010; 24: 73-86.
73. Gui L, Duan W, Tian H, et al. Adenosine A 2A receptor deficiency reduces striatal glutamate outflow and attenuates brain injury induced by transient focal cerebral ischemia in mice. Brain Res 2009; 1297: 185-93.
74. Adén U, Halldner L, Lagercrantz H, Dalmau I, Ledent C, Fredholm BB. Aggravated brain damage after hypoxic ischemia in immature adenosine A2A knockout mice. Stroke 2003; 34: 739-44.
75. Chen JF, Pedata F. Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptors. Curr Pharm Des 2008; 14: 1490-9.
76. Shen HY, Coelho JE, Ohtsuka N, et al. A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J Neurosci 2008; 28: 2970-5.
77. Ferre S. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology 1997; 133: 107-20.
78. Fredholm B, Chen JF, Masino SA, Vaugeois JM. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 2005; 45: 385-412.
79. Rangarajan S, Enserink JM, Kuiperij HB, et al. Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the beta 2-adrenergic receptor. J Cell Biol 2003; 160: 487-93.
80. Nemeth ZH, Leibovich SJ, Deitch EA, et al. Adenosine stimulates CREB activation in macrophages via a p38 MAPK-mediated mechanism. Biochem Biophys Res Commun 2003; 312: 883-8.
81. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 2003; 15: 813-27.
82. Revan S, Montesinos MC, Naime D, Landau S, Cronstein BN. Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. J Biol Chem 1996; 271: 17114-8.
83. De Ponti C, Carini R, Alchera E, et al. Adenosine A2A receptormediated, normoxic induction of HIF-1 through PKC and PI-3Kdependent pathways in macrophages. J Leukoc Biol 2007; 82: 392-402.
84. Csóka B, Németh ZH, Virág L, et al. A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood 2007; 110: 2685-95.
85. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNFalpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996; 157: 4634-40.
86. Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N, Cronstein BN. Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic Thp-1 cells. J Immunol 2001; 167: 4026-32.
87. Leibovich SJ, Chen JF, Pinhal-Enfield G, et al. Synergistic upregulation of vascular endothelial growth factor expression in murine macrophages by adenosine A2A receptor agonists and endotoxin. Am J Pathol 2002; 160: 2231-44.
88. Pinhal-Enfield G, Ramanathan M, Hasko G, et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am J Pathol 2003; 163: 711-21.
89. Schnurr M, Toy T, Shin A, et al. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood 2004; 103: 1391-7.
90. Panther E, Corinti S, Idzko M, et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 2003; 101: 3985-90.
91. Cronstein BN, Levin RI, Philips M, Hirschhorn R, Abramson SB, Weissmann G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol 1992; 148: 2201-6.
92. Sullivan GW, Lee DD, Ross WG, et al. Activation of A2A adenosine receptors inhibits expression of α4/β1 integrin (very late antigen- 4) on stimulated human neutrophils. J Leukoc Biol 2004; 75: 127-34.
93. Cronstein BN, Daguma L, Nichols D, Hutchison AJ, Williams M. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest 1990; 85: 1150-7.
94. McColl SR, St-Onge M, Dussault AA, et al. Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils. FASEB J 2006; 20:187-9.
95. Zhao ZQ, Sato H, Williams MW, Fernandez AZ, Vinten-Johansen J. Adenosine A2-receptor activation inhibits neutrophil-mediated injury to coronary endothelium. Am J Physiol 1996; 271: H1456-64.
96. Heyn J, Ledderose C, Hinske LC, et al. Adenosine A2A Receptor Up-Regulation in Human PMN is controlled by miRNA-214, miRNA-15, and miRNA-16. Shock 2012; 37: 156-63.
97. Romio M, Reinbeck B, Bongardt S, Hüls S, Burghoff S, Schrader J. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Am J Physiol Cell Physiol 2011; 301: C530-9.
98. Alam MS, Kurtz CC, Wilson JM, et al. A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. Mucosal Immunol 2009; 2: 232-42.
99. Csóka B, Himer L, Selmeczy Z, et al. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J 2008; 22: 3491-9.
100. Sevigny CP, Li L, Awad AS, et al. Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol 2007; 178: 4240-9.
101. Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, Gorelik E. Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 2005; 175: 4383-91.
102. Yamamura T, Sakuishi K, Illés Z, Miyake S. Understanding the behavior of invariant NKT cells in autoimmune diseases. J Neuroimmunol 2007; 191: 8-15.
103. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-65.
104. Naganuma M, Wiznerowicz EB, Lappas CM, Linden J, Worthington MT, Ernst PB. Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol 2006; 177: 2765-9.
105. Beldi G, Wu Y, Banz Y, et al. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis. Hepatology 2008; 48: 841-52.
106. Häusler SF, Montalbán del Barrio I, Strohschein J, et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosinegenerating enzymes responsible for adenosine receptor 2Adependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother 2011; 60: 1405-18.
107. Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 2006; 103: 13132-7.
108. Yoon JW, Jun HS. Cellular and molecular roles of beta cell autoantigens, macrophages and T cells in the pathogenesis of autoimmune diabetes. Arch Pharm Res 1999; 22: 437-47.
109. Zipris D. Innate immunity and its role in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2008; 15: 326-31.
110. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009; 5: 219-26.
111. Beyan H, Buckley LR, Yousaf N, Londei M, Leslie RD. A role for innate immunity in type 1 diabetes? Diabetes Metab Res Rev 2003; 19: 89-100.
112. Kawasaki E, Abiru N, Eguchi K. Prevention of type 1 diabetes: from the view point of beta cell damage. Diabetes Res Clin Pract 2004; 66: S27-32.
113. Chong MM, Chen Y, Darwiche R, et al. Suppressor of cytokine signaling-1 overexpression protects pancreatic beta cells from CD8+ T cell-mediated autoimmune destruction. J Immunol 2004; 172: 5714-21.
114. Phillips JM, Parish NM, Bland C, Sawyer Y, De La Peña H, Cooke A. Type 1 Diabetes Development Requires Both CD4+ and CD8+ T cells and Can Be Reversed by Non-Depleting Antibodies Targeting Both T Cell Populations. Rev Diabet Stud 2009; 6: 97-103.
115. Grunnet LG, Aikin R, Tonnesen MF, et al. Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells. Diabetes 2009; 58: 1807-15.
116. Kunz M, Ibrahim SM. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm 2009; 2009: Article ID 979258. Available from: http://www.hindawi.com/journals/mi/2009/979258/cta/
117. McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007; 8: 1390-7.
118. Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006;18:670-5.
119. Bradshaw EM, Raddassi K, Elyaman W, et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol 2009; 183: 4432-9.
120. Miljkovic D, Cvetkovic I, Momcilovic M, Maksimovic-Ivanic D, Stosic-Grujicic S, Trajkovic V. Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells. Cell Mol Life Sci 2005; 62: 2658-68.
121. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 2009; 39: 216-24.
122. Bending D, De la Peña H, Veldhoen M, et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD.scid recipient mice. J Clin Invest 2009; 119: 565-72.
123. Sutherland AP, Van Belle T, Wurster AL, et al. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009; 58: 1144-55.
124. Emamaullee JA, Davis J, Merani S, et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009; 58: 1302-11.
125. Xiong JJ, Lu HM, Du XJ, Ke NW, Hu WM. Study on the role of Th17 cells in the islet transplantation. Sichuan Da Xue Xue Bao Yi Xue Ban 2010; 41: 638-43.
126. Wang R, Han G, Wang J, et al. The pathogenic role of interleukin- 27 in autoimmune diabetes. Cell Mol Life Sci 2008; 65: 3851-60.
127. Gray JD. The role of transforming growth factor beta in the generation of suppression: an interaction between CD8+ T cells and NK cells. J Exp Med 1994; 180: 1937-42.
128. Lee IF, Qin H, Trudeau J, Dutz J, Tan R. Regulation of autoimmune diabetes by complete Freund's adjuvant is mediated by NK cells. J Immunol 2004; 172: 937-42.
129. Alba A, Planas R, Clemente X, et al. Natural killer cells are required for accelerated type 1 diabetes driven by interferon-beta. Clin Exp Immunol 2008; 151: 467-75.
130. Maruyama TK, Watanabe K, Takei I, et al. Anti-asialo GM1antibody suppression of cyclophosphamide-induced diabetes in NOD mice. Diabetes Res 1991; 17: 37-41.
131. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumour immune responses in vivo. Nat Med 1999; 5: 405-11.
132. Yuan D, Koh CY, Wilder JA. Interactions between B lymphocytes and NK cells. FASEB 1994; 8: 1012-8.
133. Gur C, Enk J, Kassem SA, et al. Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. J Immunol 2011;187: 3096-103.
134. Novak J, Griseri T, Beaudoin L, Lehuen A. Regulation of type 1 diabetes by NKT cells. Int Rev Immunol 2007; 26: 49-72.
135. Strober S. Natural killer 1.1(+) T cells and natural suppressor T cells in the bone marrow. J Allergy Clin Immunol 2000; 106: S113-4.
136. Blumenfeld HJ, Tohn R, Haeryfar SM, Liu Y, Savage PB, Delovitch TL. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in nonobese diabetic mice. Clin Exp Immunol 2011; 166: 121-33.
137. Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23: 447-85.
138. Wilson SB, Delovitch TL. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 2003; 3: 211-22.
139. Ly D, Tohn R, Rubin B, Blumenfeld H, Besra GS, Veerapen N, Porcelli SA, et al. An alpha-galactosyl ceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cellindependent responses that prevent type 1diabetes. Clin Exp Immunol 2010; 160: 185-98.
140. Sauer AV, Brigida I, Carriglio N, Hernandez RJ, Scaramuzza S, Clavenna D, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID Blood 2012; 119: 1428-39.
141. Nitta T, Itoh T, Matsuoka N, et al. Prevention of early loss of transplanted islets in the liver of mice by adenosine. Transplantation 2009; 88: 49-56.
142. Simoni Y, Gautron AS, Beaudoin L, et al. NOD mice contain an elevated frequency of iNKT17 cells that exacerbate diabetes. Eur J Immunol 2011; 41: 3574-85.
143. Rønn SG, Börjesson A, Bruun C, et al. Suppressor of cytokine signalling-3 expression inhibits cytokine-mediated destruction of primary mouse and rat pancreatic islets and delays allograft rejection. Diabetologia 2008; 51: 1873-82.
144. Suo GJ, Qin J, Zhong CP, Zhao ZX. Suppressor of cytokine signaling 1 inhibits apoptosis of islet grafts through caspase 3 and apoptosis- inducing factor pathways in rats. Transplant Proc 2010; 42: 2658-61.
145. Solomon M, Flodström-Tullberg M, Sarvetnick N. Beta-cell specific expression of suppressor of cytokine signaling-1 (SOCS-1) delays islet allograft rejection by down-regulating Interferon Regulatory Factor-1 (IRF-1) signaling. Transpl Immunol 2011; 24: 181-8.
146. Kim KA, Lee MS. Recent progress in research on beta-cell apoptosis by cytokines. Front Biosci 2009; 14: 657-64.
147. Plesner A, Soukhatcheva G, Korneluk RG, Verchere CB. XIAP inhibition of β-cell apoptosis reduces the number of islets required to restore euglycemia in a syngeneic islet transplantation model. Islets 2010; 2: 18-23.
148. Kumareswaran K, Evans ML, Hovorka R. Artificial pancreas: an emerging approach to treat Type 1 diabetes. Expert Rev Med Devices 2009; 6: 401-10.
149. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. The effect of intensive insulin therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-9.
150. Corrêa-Giannella ML, Raposo do Amaral AS. Pancreatic islet transplantation. Diabetol Metab Syndr 2009; 1: 9. Available from: http://www.dmsjournal.com/content/1/1/9
151. Bellin MD, Kandaswamy R, Parkey J, et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008; 8: 2463-70.
152. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318-30.
153. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal- dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830-35.
154. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-9.
155. Chhabra P, Brayman KL. Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation. J Transplant 2011; 2011: Article ID 637692. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3199196/?tool=pub med
156. Chhabra P, Kensinger C, Moore D, Brayman K. Present Accomplishments and Future Prospects of Cell-Based Therapies for Type 1 Diabetes. In: David Wagner, Ed. Type 1 Diabetes - Pathogenesis, Genetics and Immunotherapy. InTech, Croatia 2011; pp. 295-336.
157. Huang X, Moore DJ, Ketchum RJ, et al. Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation. Endocr Rev 2008; 29: 603-30.
158. Chhabra P, Mirmira RG, Brayman KL. Regenerative medicine and tissue engineering: contribution of stem cells in organ transplantation. Curr Opin Organ Transplant 2009; 14: 46-50.
159. Matsumoto S, Noguchi H, Takita M, et al. ET-Kyoto ductal injection and density-adjusted purification combined with potent antiinflammatory strategy facilitated single-donor islet transplantation: case reports. Transplant Proc 2010; 42: 2159-61.
160. Matsumoto S, Okitsu T, Iwanaga Y, et al. Follow-up study of the first successful living donor islet transplantation. Transplantation 2006; 82: 1629-33.
161. Alejandro R, Barton FB, Hering BJ, Wease S, Collaborative Islet Transplant Registry Investigators. 2008 Update from the Collaborative Islet Transplant Registry. Transplantation 2008; 86: 1783-8.
162. Fiorina P, Shapiro AM, Ricordi C, Secchi A. The clinical impact of islet transplantation. Am J Transplant 2008; 8: 1990-7.
163. Sakowicz-Burkiewicz M, Kocbuch K, Grden M, Szutowicz A, Pawelczyk T. Diabetes-induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytes. Immunology 2006; 118: 402-12.
164. Celiński K, Prozorow-Król B, Korolczuk A, et al. The role of adenosine A2A receptors in experimental acute pancreatitis. Adv Med Sci 2006; 51: 105-10.
165. Duarte JM, Oliveira CR, Ambrósio AF, Cunha RA. Modification of adenosine A1 and A2A receptor density in the hippocampus of streptozotocin-induced diabetic rats. Neurochem Int 2006; 48: 144-50.
166. Zarek PE, Huang CT, Lutz ER, et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 2008; 111: 251-9.
167. Yasunami Y, Kojo S, Kitamura H, Toyofuku A, et al. Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets. J Exp Med 2005; 202: 913-8.
168. Toyofuku A, Yasunami Y, Nabeyama K et al. Natural killer T-cells participate in rejection of islet allografts in the liver of mice. Diabetes 2006; 55: 34-39.
169. Satoh M, Yasunami Y, Matsuoka N, Nakano M, Itoh T, Nitta T, et al. Successful islet transplantation to two recipients from a single donor by targeting proinflammatory cytokines in mice. Transplantation 2007; 83: 1085-92.
170. Ghaemi Oskouie F, Shameli A, Yang A, et al. High levels of adenosine deaminase on dendritic cells promote autoreactive T cell activation and diabetes in nonobese diabetic mice. J Immunol 2011; 186: 6798-806.
171. Chhabra P, Wang K, Zeng Q, et al. Adenosine A(2A) agonist administration improves islet transplant outcome: Evidence for the role of innate immunity in islet graft rejection. Cell Transplant 2010; 19: 597-612.
172. Bowers DT, Chhabra P, Langman L, Botchwey EA, Brayman KL. FTY720-loaded poly(DL-lactide-co-glycolide) electrospun scaffold significantly increases microvessel density over 7 days in streptozotocin- induced diabetic C57b16/J mice: preliminary results. Transplant Proc 2011; 43: 3285-7.
173. Katebi M, Soleimani M, Cronstein BN. Adenosine A2A receptors play an active role in mouse bone marrow-derived mesenchymal stem cell development. J Leukoc Biol 2009; 85: 438-44.
174. Boumaza I, Srinivasan S, Witt WT, et al. Autologous bone marrow- derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun 2009; 32: 33-42.
175. Ito T, Itakura S, Todorov I, et al. Mesenchymal stem cell and islet co-transplantation promotes graft revascularization. Transplantation 2010; 89: 1438-45.
176. Rackham CL, Chagastelles PC, Nardi NB, Hauge-Evans AC, Jones PM, King AJ. Cotransplantation of mesenchymal stem cells maintains islet organisation and morphology in mice. Diabetologia 2011; 54: 1127-35.